R. Aumann et al. / Journal of Organometallic Chemistry 617–618 (2001) 322–328
327
ꢀC(OEt)CH3], 0.56 (3H, t, OCH2CH3). 13C-NMR
(CDCl3): l 253.8 (WꢂC), 212.3 and 198.7 [1:4, trans-
and cis-CO, W(CO5], 165.3 (Cq, COOCH2Ph); 147.8,
146.2 and 139.6 (Cq each; C1%, C2 and C3), 135.7 and
131.9 (Cq each, iC Ph), 129–127 (CH, Ph and CH2Ph),
119.9 (CH, C4); 67.2, 66.6, 66.1, 63.8 and 62.6 (OCH2
each; morpholine, OCH2C6H5 and OCH2CH3), 52.9
(2NCH2, morpholine), 16.7 [ꢀC(OEt)CH3], 14.0
(OCH2CH3). IR (diffuse reflection), cm−1: 2058.3 (20),
1927.0 (90), 1902.1 (100) [w(CꢁO], 1721.3 (20) [w(CꢀO].
MS (70 eV, m/e (%), 184W: 419 (50) [M+ꢂW(CO5)], 339
(100), 91 (100) [CH2Ph+]. Anal. Found: C, 44.73; H,
4.16; N, 1.61. Calc. for (C31H29NO9W×CHCl3)
(862.8): C, 44.55; H, 3.50; N, 1.63%.
COOCMe3), 153.1 (Cq, C3), 139.9 and 135.8 (Cq each,
C2 and iC Ph); 128.1, 127.6 and 126.9 (CH each, Ph),
123.5 (CH, C4), 79.7 (CMe3), 74.1 (OCH2CH3), 66.2
(2OCH2, morpholine), 52.3 (2NCH2, morpholine), 27.5
[C(CH3)3], 25.8 (NCCH3), 15.3 (OCH2CH3). IR (dif-
fuse reflection), cm−1: 2058.6 (20), 1966.9 (90), 1935.6
(100) [w(CꢁO], 1708.7 (20) [w(CꢀO].
3.4.3. Compound 6d
1H-NMR (CDCl3): l 7.25 (5H, s, Ph), 5.26 (1H, s,
4-H), 4.60–3.10 (10H, m, OCH2 and NCH2 morpholine
each, and OCH2CH3), 1.78 [3H, s, ꢀC(OEt)CH3], 1.07
[9H, s, C(CH3)3], 0.59 (3H, t, OCH2CH3). 13C-NMR
(CDCl3): l 254.2 (WꢂC), 202.5 and 199.1 [1:4, trans-
and cis-CO, W(CO5], 165.6 (Cq, COOCMe3); 145.5,
145.0 and 140.6 (Cq each; C1%, C2 and C3), 131.2 (Cq,
iC Ph); 128.1, 127.6 and 126.9 (CH each, Ph), 122.7
(CH, C4), 80.2 (CMe3); 66.7, 66.3, 63.7 and 62.5
(2OCH2 and 1NCH2 morpholine each, and OCH2CH3),
52.8 (NCH2 morpholine), 27.8 [C(CH3)3], 16.6
[ꢀC(OEt)CH3], 14.1 (OCH2CH3). MS (70 eV), m/e (%),
184W: 709 (10) [M+], 569 (10) [M+ꢂ5CO], 385 (20)
[ligand], 57 (100). Anal. Found: C, 47.78; H, 4.21; N,
2.67. Calc. for C28H31NO9W (709.4): C, 47.41; H, 4.40;
N, 1.97%.
3.4. Pentacarbonyl[1-ethoxy-5-(t-butoxy)-2-
(1-morpholinium-1-ethylidene)-5-oxo-3-phenyl-
penta-1,3-dien-1-yl]tungstate [(1E)- and (1Z)-5d] and
pentacarbonyl[2-(1-ethoxy-ethylidene)-5-(t-butoxy)-
1-morpholinium-5-oxo-3-phenyl-3-penten-1-yl]tungstate
(6d)
A
mixture of pentacarbonyl(1-ethoxy-3-phenyl-2-
propin-1-ylidene)tungsten (1a, 482 mg, 1.00 mmol) and
3-morpholino-but-2-enoic acid t-butylester (4c, 203 mg,
1.00 mmol) in 20 ml of n-pentane is reacted as de-
scribed above to give compound (1E)-5d [631 mg, 89%,
m.p. (dec.) 99°C, Rf=0.1 in diethyl ether–pentane
(1:1)]. (1E)-5d in CDCl3 solution undergoes an isomeri-
sation within 24 h at 20°C to give compound (1Z)-5c
and 6c in a molar ratio 1:6.
3.5. Pentacarbonyl[1-ethoxy-5-(t-butoxy)-2-
(1-morpholinium-1-ethylidene)-5-oxo-3,4-bis(phenyl)-
penta-1,3-dien-1-yl]tungstate [(1E)-5e] and
pentacarbonyl[2-(1-ethoxy-ethylidene)-5-(t-butoxy)-
1-morpholinium-5-oxo-3,4-bis(phenyl)-3-penten-1-yl]
tungstate (6e)
3.4.1. (1E)-5d
1H-NMR (C6D6, 360 MHz): l 7.35 and 7.05 (2:3H,
Ph), 5.97 (1H, s, 4-H), 4.19 (2H, diastereotopic
OCH2CH3), 2.90 (4H, m, 2OCH2 morpholine), 2.80
(4H, m, NCH2 morpholine), 1.70 (3H, s, NCCH3) 1.30
[9H, s, C(CH3)3], 0.93 (3H, t, OCH2CH3). 13C-NMR
(CDCl3, 242 K): l 252.2 (WꢂC), 203.2 and 199.4 [1: 4,
trans- and cis-CO, W(CO5], 180.1 (Cq, CꢀN+), 165.9
(Cq, COOCMe3), 154.3 (Cq, C3), 139.4 and 134.6 (Cq
each, C2 and iC Ph); 128.9, 128.5 and 127.5 (CH each,
Ph), 123.1 (CH, C4), 79.9 (CMe3), 73.7 (OCH2CH3),
66.2 (2OCH2 morpholine), 51.7 (2NCH2 morpholine),
27.4 (CMe3), 26.2 (OCH2CH3), 15.2 (NCCH3). IR
(diffuse reflection), cm−1: 2050.6 (20), 1900.2 (100)
[w(CꢁO], 1703.6 (20) [w(CꢀO].
A mixture of pentacarbonyl(1-ethoxy-3-phenyl-2-
propin-1-ylidene)tungsten (1a, 482 mg, 1.00 mmol) and
2-morpholino-1-phenyl-propene (4d, 170 mg, 1.00
mmol) in 20 ml of n-pentane is reacted as described
above to give compound (1E)-5e (500 mg, 90%). (1E)-
5e in CDCl3 solution undergoes an isomerisation within
24 h at 20°C to give compound 6e as the only product.
3.5.1. (1E)-5e
1H-NMR (CDCl3): l 7.40–7.00 (10H, m, Ph), 6.80
(1H, s, 4-H), 4.28 (2H, q, OCH2CH3), 3.60 (4H, m,
diastereotopic OCH2 morpholine), 3.49 (4H, m,
diastereotopic NCH2 morpholine), 2.18 (3H, s,
NCCH3), 1.22 (3H, t, OCH2CH3).
3.4.2. (1Z)-5d
3.5.2. Compound 6e
1H-NMR (CDCl3): l 7.52 and 7.25 (2:3 H, m each,
Ph), 6.19 (1H, s, 4-H), 4.22 (2H, diastereotopic
OCH2CH3), 3.87 (4H, m, 2OCH2 morpholine), 3.75
(4H, m, 2NCH2 morpholine), 2.34 (3H, s, NCCH3),
1.45 [9H, s, C(CH3)3], 1.14 (3H, OCH2CH3). 13C-NMR
(CDCl3): l [9] (WꢂC), 202.9 and 199.8 [1: 4, trans- and
cis-CO, W(CO5], 178.0 (Cq, CꢀN), 165.9 (Cq,
1H-NMR (CDCl3): l 7.30–6.80 (10H, m, Ph), 6.04
(1H, s, 4-H), 4.70–3.00 (10H, m, OCH2 and NCH2,
morpholine each, and OCH2CH3), 1.76 (3H, s, CH3),
0.54 (3H, t, OCH2CH3). 13C-NMR (CDCl3): l 254.7
(WꢀC), 203.1 and 198.9 [1: 4, trans- and cis-CO,
W(CO)5]; 142.5, 141.0 and 133.7 (Cq each; C1%, C2 and
C3), 137.1 and 135.1 (Cq each, iC Ph), 131–126 (CH